Similar articles

• Selective Pneumocystis carinii dihydrofolate reductase inhibitors: design, synthesis, and biological evaluation of new 2,4-diamino-5-substituted-furo[2,3-d]pyrimidines.

  Gangjee A, Guo X, Queener SF, Cody V, Galitsky N, Luft JR, Pangborn W. Gangjee A, et al. J Med Chem. 1998 Apr 9;41(8):1263-71. doi: 10.1021/jm970537w. J Med Chem. 1998. PMID: 9548816
• Biochemical pharmacology of lipophilic diaminopyrimidine antifolates in mouse and human cells in vitro.

  Greco WR, Hakala MT. Greco WR, et al. Mol Pharmacol. 1980 Nov;18(3):521-8. Mol Pharmacol. 1980. PMID: 6970329 No abstract available.
• New 2,4-diamino-5-(2',5'-substituted benzyl)pyrimidines as potential drugs against opportunistic infections of AIDS and other immune disorders. Synthesis and species-dependent antifolate activity.

  Rosowsky A, Forsch RA, Sibley CH, Inderlied CB, Queener SF. Rosowsky A, et al. J Med Chem. 2004 Mar 11;47(6):1475-86. doi: 10.1021/jm030438k. J Med Chem. 2004. PMID: 14998335
• Dihydrofolate reductase inhibitors as antibacterial agents.

  Hawser S, Lociuro S, Islam K. Hawser S, et al. Biochem Pharmacol. 2006 Mar 30;71(7):941-8. doi: 10.1016/j.bcp.2005.10.052. Epub 2005 Dec 13. Biochem Pharmacol. 2006. PMID: 16359642 Review.
• Eukaryotic dihydrofolate reductase.

  Blakley RL. Blakley RL. Adv Enzymol Relat Areas Mol Biol. 1995;70:23-102. doi: 10.1002/9780470123164.ch2. Adv Enzymol Relat Areas Mol Biol. 1995. PMID: 8638484 Review. No abstract available.